Citalopram for Agitation in Alzheimer’s disease (CITAD): A Multicenter Clinical Trial. The purpose of this study funded by the US NIA (National Institute of Aging) is to examine the efficacy and safety of citalopram vs. placebo in the treatment of clinically significant agitation in patients with Alzheimer’s diseases.
Relation of Beta-Amyloid to Psychiatric Disturbances in Dementia :The purpose of this study funded by the US NIA (National Institute of Aging) is to see whetheramyloid plaques in the brain appear in late-onset frontotemporal dementia to an extent similar to normal aging or Alzheimer’s disease.